Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)
1 other identifier
interventional
360
1 country
1
Brief Summary
This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Sep 2001
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2001
CompletedFirst Submitted
Initial submission to the registry
November 20, 2001
CompletedFirst Posted
Study publicly available on registry
November 21, 2001
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2004
CompletedDecember 10, 2007
December 1, 2007
November 20, 2001
December 7, 2007
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Current diagnosis of alcohol dependence.
- Provide a written informed consent.
- Must weigh within 30% of their ideal body weight.
- Patients must weigh at least 89 lbs. and no more than 342 lbs.
- Good physical health.
- Currently drinking 14 or more alcohol units per week for women and 21 or more alcohol units per week for men in the last 30 days.
- Provide evidence of stable residence in the last month prior to enrollment in the study.
- No plans to move in the nine months after entering the study.
- Literate in English and able to read, understand, and complete questionnaires and follow instructions.
- Willingness to participate in behavioral treatment for alcoholism.
You may not qualify if:
- Current psychiatric disorder other than alcohol or nicotine dependence.
- Elevated liver enzymes or elevated bilirubin.
- Severe alcohol withdrawal symptoms which require treatment.
- Serious medical co-morbidity requiring medical intervention or close supervision.
- Severe or life-threatening adverse reactions to medications in the past or during this trial.
- Female patients who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study.
- Received inpatient or outpatient treatment for alcohol dependence within the last 30 days.
- Compelled to participate in an alcohol treatment program for alcohol dependence to maintain their liberty.
- Members of the same household.
- Tuberculosis.
- Current treatment with any medications having a potential effect on alcohol consumption and related behaviors or mood.
- Urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs.
- Pyrexia of unknown origin.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas Health Science Center
San Antonio, Texas, 78229, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
November 20, 2001
First Posted
November 21, 2001
Study Start
September 1, 2001
Study Completion
August 1, 2004
Last Updated
December 10, 2007
Record last verified: 2007-12